Doc 1263 Filed 10/22/25 Page 1 of 10 Docket #1263 Date Filed: 10/22/2025 Case 18-10518-JTD

UNITED STATES BANKRUPTCY COURT

	FOR THE	DISTRICT OF	DELAWARE		
In re: Orexigen Therapeutics, Inc.		§ §	Case No.	18-10518	
Debtor(s)		§ §	☐ Jointly	Administered	
Post-confirmation Report					Chapter 11
Quarter Ending Date: 09/30/2025			Petit	ion Date: <u>03/12/2018</u>	<u> </u>
Plan Confirmed Date: 05/17/2019			Plan Effect	ive Date: <u>05/31/2019</u>)
This Post-confirmation Report relates to:	_		ntity: Wind-Down A	administrator	
		,		uthorized Party or	
/s/ Andrew C. Ehrmann		And	drew C. Ehrmann		

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.

Printed Name of Responsible Party

Potter Anderson & Corroon LLP

1313 N. Market St., 6th Floor, Wilmington, DE 19801-6108

Address



Signature of Responsible Party

10/22/2025

Date

Case No. 18-10518

Part 1: Summary of Post-confirmation Transfers

	Current Quarter	Total Since Effective Date
a. Total cash disbursements	\$6,649	\$11,033,677
b. Non-cash securities transferred	\$0	\$0
c. Other non-cash property transferred	\$0	\$0
d. Total transferred (a+b+c)	\$6,649	\$11,033,677

			Approved Current	Approved Cumulative	Paid Current Quarter	Paid Cumulative
Profess incurre	sional fees & expenses (bankruptcy) ed by or on behalf of the debtor	Aggregate Total	\$0	\$100,985	\$0	\$100,98
Itemize	ed Breakdown by Firm					
	Firm Name	Role				
i	Potter Anderson & Corroon LL	Special Counsel	\$0	\$16,280	\$0	\$16,28
ii	Quinn Emanuel Urquhart & Su	Special Counsel	\$0	\$84,705	\$0	\$84,70
iii						
iv						
V						
vi						
vii						
viii						
ix						
X						
xi						
xii						
xiii						
xiv						
XV						
xvi						
xvii						
xviii						
xix						
xx						
xxi						
xxii						
xxiii						
xxiv						
XXV						
xxvi						
xxvii						
xxviii						
xxix						

xxx				
xxxi				
xxxi	i			
xxxi	ii			
xxxi	v			
XXXV	,			
XXXV	i			
XXXV	ii			
XXXV	iii			
xxxi	X			
xl				
xli				
xlii				
xliii				
xliv				
xlv				
xlvi				
xlvii				
xlvii	i			
xlix				
l				
li				
lii				
liii				
liv				
lv				
lvi				
lvii				
lviii				
lix				
lx				
lxi				
lxii				
lxiii				
lxiv				
lxv				
lxvi				
lxvii				
lxvii	i			
lxix				
lxx				
lxxi				

Case 18-10518-JTD Doc 1263 Filed 10/22/25 Page 4 of 10

Debtor's Name Orexigen Therapeutics, Inc.

Case No. 18-10518

Decili D					
Exxiv Exxi	lxxii				
	lxxiii				
	lxxiv				
	lxxv				
Ixxii	lxxvi				
Exxit Exxi	lxxvii				
	lxxviii				
	lxxix				
	lxxx				
	lxxxi				
	lxxxii				
	lxxxiii				
	lxxxiv				
Ixxxvii	lxxxv				
lxxxii	lxxxvi				
lxxxix xc	lxxxvii				
xc xci xcii xciii xciv xcv xcv xcvi xcvii xcviii xcix xcix c xcvii	lxxxvii				
xci xcii xciii xcii xciv xcii xcv xcvi xcvii xcviii xcviii xcii xcix xcix c xcix	lxxxix				
xcii	xc				
xciii	xci				
xciv	xcii				
xcvi	xciii				
xcvi	xciv				
xcvii xcviii xcviii c	xcv				
xcviii xcix c	xcvi				
xcix c	xcvii				
c	xcviii			_	_
	xcix				
ci	c				
	ci				

					Approved Current	Approved Cumulative	Paid Current Quarter	Paid Cumulative
b.	Professincurre	sional fees & expenses (non ed by or on behalf of the de	nbankruptcy) ebtor	Aggregate Total	\$0	\$0	\$0	\$0
	Itemiz	ed Breakdown by Firm						
		Firm Name		Role				
	i	N/A			\$0	\$0	\$0	\$0
	ii							
	iii							
	iv							
	v							
	vi							

	vii			
	viii			
	ix			
	x			
	xi			
	xii			
	xiii			
	xiv			
Ī	xv			
	xvi			
	xvii			
İ	xviii			
	xix			
	xx			
ļ	xxi			
	xxii			
	xxiii			
	xxiv			
İ	XXV			
İ	xxvi			
İ	xxvii			
İ	xxviii			
İ	xxix			
İ	XXX			
İ	xxxi			
İ	xxxii			
İ	xxxiii			
İ	xxxiv			
İ	XXXV			
İ	xxxvi			
	xxxvii			
İ	xxxviii			
İ	xxxix			
İ	xl			
İ	xli			
İ	xlii			
L	xliii			
L	xliv			
L.	xlv			
_ L	xlvi			
L	xlvii			
L	xlviii			
	(X1 4 111			

Nix					
		dix			
III		i			
		ii			
Iv V V V V V V V V V	L				
No. No.	L				
Ivi Ivi	⊢				
Iviii	-	vi			
Ix	ŀ	vii			
No. No.		viii			
bx	-	ix			
bxi	L				
Description Description		xi			
Description Description	L				
Date Date	ŀ				
Devit Devi		xiv			
Inviti		xv			
December 1 December 2 Dec		xvi			
Dax Dax		xvii			
Dxx Dxxii Dxxiii Dxxiii Dxxiv Dxxv Dxxv Dxxvii Dxxviii Dxxxxiii Dxxxxiii Dxxxxiii Dxxxxiii Dxxxxiii Dxxxxiii Dxxxxiii Dxxxxiii Dxxxxiii Dxxxxiii Dxxxxiii Dxxxxiii Dxxxxiii Dxxxxiii Dxxxxiii Dxxxxiii Dxxxxiii Dxxxxiii Dxxxxxiii Dxxxxxiii Dxxxxxiii Dxxxxxiii Dxxxxxiii Dxxxxxiii Dxxxxxiii Dxxxxxiii Dxxxxxiii Dxxxxxxiii Dxxxxxxxiii Dxxxxxxiii Dxxxxxxxiii Dxxxxxxxiii Dxxxxxxxiii Dxxxxxxxiii Dxxxxxxxiii Dxxxxxxxiii Dxxxxxxxiii Dxxxxxxxxxii Dxxxxxxxxiii Dxxxxxxxxiii Dxxxxxxxxiii Dxxxxxxxxiii Dxxxxxxxxiii Dxxxxxxxxiii Dxxxxxxxxiii Dxxxxxxxxiii Dxxxxxxxxiii Dxxxxxxxxxx		xviii			
		xix			
Dexii		xx			
Description Description		xxi			
		xxii			
		xxiii			
	ŀ	xxiv			
		xxv			
lxxix		xxvi			
lxxx	ŀ	xxvii			
lxxxi	-	xxviii			
lxxxii lxxxiii lxxxiv lxxxv lxxxv lxxxvi lxxxvii lxxxvii		xxix			
lxxxii lxxxiv lxxxv lxxxv lxxxvi lxxxvii lxxxxvii lxxxxvii	1	xxx	 		
lxxxiv lxxxv lxxxvi lxxxvii lxxxvii lxxxxvii	-	xxxi	 		
lxxxv lxxxvi lxxxvii lxxxvii lxxxxii	[xxxii	 		
lxxxvi lxxxvii lxxxvii lxxxxii	-	xxxiii	 	 	
lxxxvii lxxxvii lxxxxii	-	xxxiv			
lxxxvii lxxxvii	-	xxxv			
lxxxvii lxxxix		xxxvi			
lxxxix		xxxvii			
		xxxvii	 	 	
		xxxix			
xc	:	xc			

Case 18-10518-JTD Doc 1263 Filed 10/22/25 Page 7 of 10

	ics Inc				Case No. 18-1051	Q
ebtor's Name Orexigen Therapeuti	es, me.				Case No. 10-1031	.0
xci						
xcii						
xciii						
xciv						
xcv						
xcvi						
xcvii						
xcviii						
xcix						
c						
ci						
All professional fees and ex	penses (debtor & commit	tees)	\$0	\$100,98	5 \$0	\$100,9
art 3: Recoveries of the Holders of	Claims and Interests und	er Confirmed Plan				
art 5. Accoveries of the Holders of						
	Total Anticipated	D.I.G				% Paid of
	Total	Paid Current Quarter	Paid Cun	nulative	Allowed Claims	% Paid of Allowed Claims
a. Administrative claims	Total Anticipated Payments		Paid Cun	nulative \$0	Allowed Claims \$192,468	Allowed Claims
a. Administrative claims b. Secured claims	Total Anticipated Payments Under Plan	Quarter				Allowed Claims
	Total Anticipated Payments Under Plan	Quarter \$0		\$0	\$192,468	Allowed Claims 0%
b. Secured claims	Total Anticipated Payments Under Plan \$0 \$1,162,758	Quarter \$0 \$0	\$8	\$0 8,537,068	\$192,468 \$165,000,000	Allowed
b. Secured claims c. Priority claims	Total Anticipated Payments Under Plan \$0 \$1,162,758 \$90,795	Quarter \$0 \$0 \$0 \$0	\$8	\$0 8,537,068 \$90,795	\$192,468 \$165,000,000 \$90,795	Allowed Claims 0% 5% 100%
b. Secured claims c. Priority claims d. General unsecured claims e. Equity interests	Total Anticipated Payments Under Plan \$0 \$1,162,758 \$90,795 \$474,814	Quarter \$0 \$0 \$0 \$0 \$0	\$8	\$0 8,537,068 \$90,795 \$646,134	\$192,468 \$165,000,000 \$90,795	Allowed Claims 0% 59 1009
b. Secured claims c. Priority claims d. General unsecured claims	Total Anticipated Payments Under Plan \$0 \$1,162,758 \$90,795 \$474,814	Quarter \$0 \$0 \$0 \$0 \$0	\$8	\$0 8,537,068 \$90,795 \$646,134	\$192,468 \$165,000,000 \$90,795	Allowed Claims 0% 59 1009

If yes, give date Final Decree was entered:

If no, give date when the application for Final Decree is anticipated:

b. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930?

12/31/2025

Yes

No

Case 18-10518-JTD Doc 1263 Filed 10/22/25 Page 8 of 10

Debtor's Name Orexigen Therapeutics, Inc.


Case No. 18-10518

Privacy Act Statement


28 U.S.C. § 589b authorizes the collection of this information and provision of this information is mandatory. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a) (6) and to otherwise evaluate whether a reorganized chapter 11 debtor is performing as anticipated under a confirmed plan. Disclosure of this information may be to a bankruptcy trustee when the information is needed to perform the trustee's duties, or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." *See* 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case, or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

I declare under penalty of perjury that the foregoing Post-confirmation Report and its attachments, if any, are true and correct and that I have been authorized to sign this report.


/s/ Peter Kravitz	Peter Kravitz
Signature of Responsible Party	Printed Name of Responsible Party
Wind Down Administrator	10/22/2025
Title	Date




Page 1




Other Page 1




Page 2 Minus Tables




Bankruptcy Table 1-50




Bankruptcy Table 51-100



Non-Bankruptcy Table 1-5



Non-Bankruptcy Table 51-100



Part 3, Part 4, Last Page

In re *Orexigen Therapeutics, Inc.*Case No. 18-10518 (KG)

Notes to Post-Confirmation Report for the Quarter Ended September 30, 2025

Part 2b

The Wind Down Administrator has not made any payments on account of pre-confirmation professional fees and expenses.

Part 3

"Total Anticipated Payments Under Plan" reflects amounts paid plus cash on hand as of the date of this report, and is subject to reduction based on, among other things, operating expenses of the Wind Down Administrator and/or the estates.

CERTIFICATE OF SERVICE

I, Andrew C. Ehrmann, do hereby certify that on October 22, 2025, a copy of the foregoing *Chapter 11 Post-Confirmation Report for the Quarter Ending 09/30/2025* was served on the party listed below in the manner indicated.

Timothy J. Fox, Jr., Esq.
Office of the United States Trustee
844 King Street, Room 2207
Lockbox 35
Wilmington, Delaware 19801
Email: timothy.fox@usdoj.gov

Via Email

/s/ Andrew C. Ehrmann Andrew C. Ehrmann (No. 7395)